Patient speaker for NICE Committee Meeting for the first new treatment for COPD in a decade.

[AsthmaandLung]

Do you have COPD or have a friend or family member with COPD? Dupilumab is the first new treatment for patients with COPD in more than a decade.

Dupilumab could have a life-changing impact on COPD patients. It has been shown to reduce exacerbations and improve lung treatments significantly. Dupilumab is currently going through the approval process at the National Institute for Health and Care Excellence (NICE). NICE is the regulator which decides which treatments are made available on the NHS in England.

We are looking for a patient with COPD to speak at the NICE Committee meeting on the 10th of April about their experiences with COPD and how this medicine could improve their quality of life. We are hoping to find a patient with COPD who fits the below criteria, which were used for the clinical trials for Dupilumab:

Diagnosis of COPD.

Aged 40-80 years old.

Current or former smoker (who has smoked for over 10 years)

Patient-reported of a chronic cough.

A history of at least 2 moderate or 1 severe exacerbation (severe defined as requiring attendance at A+E).

This is a great opportunity to ensure that decisions to approve new treatments for COPD are informed by the lived experiences of patients. Please do let BethDo you have COPD or have a friend or family member with COPD? Dupilumab is the first new treatment for patients with COPD in more than a decade. Dupilumab could have a life-changing impact on COPD patients. It has been shown to reduce exacerbations and improve lung treatments significantly. Dupilumab is currently going through the approval process at the National Institute for Health and Care Excellence (NICE). NICE is the regulator which decides which treatments are made available on the NHS in England. We are looking for a patient with COPD to speak at the NICE Committee meeting on the 10th of April about their experiences with COPD and how this medicine could improve their quality of life. We are hoping to find a patient with COPD who fits the below criteria, which were used for the clinical trials for Dupilumab:

Diagnosis of COPD.

Aged 40-80 years old.

Current or former smoker (who has smoked for over 10 years)

Patient-reported of a chronic cough.

A history of at least 2 moderate or 1 severe exacerbation (severe defined as requiring attendance at A+E).

This is a great opportunity to ensure that decisions to approve new treatments for COPD are informed by the lived experiences of patients.

Please do let Beth know if you like to speak at the NICE Committee meeting.

[e-mail]

[Maggity]

I have been watching the progression of this drug with great interest, particularly as it was used, I believe, for psoriasis when other treatments fail. I am in Scotland and I wonder if you are aware of any movement there or if Dupilumab is approved by NICE will that cover prescribing in Scotland as well. I will follow this post with interest.Maggie

[AsthmaandLung Administrator in reply to Maggity]

Hi Maggity

This is probably all yet to be established after the trials. We will also be following the progress.

Best wishes

Helpline Team

[sassy59]

Great news and I’m sure you’ll find someone to speak about their COPD experience. Xxxx

[Rich1957]

Very interesting, I’ve sent them an email as I’ve had Dupilumab on a trial and had a great response to it ❤️

[AsthmaandLung Administrator in reply to Rich1957]

That's great to hear

[Rich1957 in reply to AsthmaandLung]

Many thanks again for your post , I’m glad to say I have been accepted as a patient expert in the upcoming NICE zoom meeting in April which will hopefully approve the use of Dupilumab for COPD sufferers.

[Patk1 in reply to Rich1957]

Congratulations Rich1957 xxxc

[islande]

does it work for all forms of copd or is that what the trail will establish does anybody know

[Rich1957 in reply to islande]

The trials have finished for now , from my understanding it will be for people who have high Eosinophilic levels and COPD with a large number of infections . It is quite similar to asthma sufferers which it is already used for as a last resort and will hopefully be for copd sufferers as well now .